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Genetics in Alzheimer's Disease
In healthy individuals, normal ageing results in several changes to the structure and functioning of 
the brain.  Reductions in the rate of production and integration of new brain cells, the degradation 
of vasculature, onset of hypertension, and reduction in white matter volume all combine to reduce 
performance of the brain’s circuitry (Brown et al., 2011; Harada et al., 2013; Manard et al., 2016; 
Peters, 2006).  Functional deficits also manifest in the form of progressive problems with specific 
types of memory brought on by biochemical changes to the levels of neurotransmitters and hormones, 
an increased susceptibility to oxidative stress and the failure of protein clearance mechanisms 
(Finkel et al., 2000; Petralia et al., 2014).  These factors progressively contribute to impediments in 
the integration and processing of signals in the brain, affecting cognition and memory performance 
(Raz et al., 1997; Terry, 2006).
In some individuals, however, decline in cognitive functioning exceeds age-related expectations, and 
can progress to such a degree that the decline in an individual’s cognitive abilities occurs earlier than 
expected.  This syndrome is referred to as dementia, and can be instigated by a variety of pathologies, 
the most common of which is Alzheimer’s disease (AD) (Alzheimer’s Disease International, 2016). 
AD first presents with symptoms of forgetting, disordered cognition and emotional disruptions, 
progressing through a worsening of cognitive and behavioural deficits to an inability to self-care, 
loss of motor control and eventually death (Lenox-Smith et al., 2016).  Alzheimer’s disease is the 
most common cause of dementia, accounting for 60-70% of all dementia cases (World Health 
Organisation, 2015).
The hallmark molecular pathologies seen in post-mortem AD brain are senile plaques formed by the 
accumulation of sticky amyloid-β fibrils, and neurofibrillary tangles caused by detrimental modification 
(hyperphosphorylation) of molecules that stabilise the cytoskeleton of neurons, called tau proteins 
(Selkoe, 1991).  The presence of these artefacts is associated with neuronal excitotoxicity, which 
occurs when the electrochemical balance of neurons becomes disrupted, causing the neurons to 
fire more readily, and leading to a build up of molecules that becomes toxic and results in synaptic 
degradation and cell death (Hynd et al., 2004).  As more cells become affected, neural circuits and 
entire regions of the brain become atrophied, causing a loss of brain tissue volume (Bobinski et 
al., 1996).  In Alzheimer’s disease, this neuronal loss spreads progressively through a predictable 
sequence of brain regions, resulting in deficits specific to the forms of memory associated with the 
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affected brain regions (Almkvist et al., 1993).  Structural changes start in the entorhinal cortex and 
the hippocampus before progressing from the front of the temporal lobe throughout the temporal 
cortex.  Memory deficits in these areas initially affect episodic types of memory (i.e. autobiographical 
memories), progressing through other forms of hippocampal associated memory such as semantic 
memory, then procedural memory (memory of general knowledge and abstract facts, then knowledge 
of how to perform basic, well rehearsed tasks)(Gold et al., 2008).  Structural atrophy then progresses 
to the association cortex, spreading throughout the secondary then primary cerebral cortex (Reid 
et al., 2013), and eventually resulting in such significant and widespread decay that basic motor 
functions are lost, and the patient cannot respond to or interact with their environment.
While a great deal of information has been gathered on AD since it was described by Dr Alois 
Alzheimer in 1905, there is still much that is unknown about the triggers of the disease.  This is 
partly because AD is a multifactorial disease, with a range of potential causes which may develop 
independently or cumulatively to significant enough pathological levels to produce the AD syndrome. 
For some people, this might mean AD develops from a single trigger, such as a causative gene, 
while for others onset might require the combination of a gene that increases AD susceptibility (but 
is not causative) with other factors such as lifestyle, educational experiences, or the presence of a 
secondary condition such as diabetes.
It is useful for both clinical and research purposes, therefore, to classify cases of AD by their age of 
onset and attributable cause, as these categories are likely to develop from different aetiologies and 
progress and respond to treatments differently.  Age of onset is defined as either early (≤60 years 
of age) or late (>60 years of age), and the attributable cause as either familial (directly inherited) 
or sporadic (resulting from an accumulation of various risk factors).   Genetic factors account for 
all cases of familial AD, and there are also several genetic risk factors, which when combined with 
certain lifestyle factors can increase susceptibility to sporadic AD (Reitz, 2015).
Familial Alzheimer’s disease is attributable to mutations in the sequences for the genes encoding 
the amyloid precursor protein (APP) or its processing enzymes (Selkoe, 1996).  Inherited forms of 
AD are typically of early onset, as the presence of the gene in itself causes sufficiently significant 
pathology to develop the disease.  Familial AD accounts for around 5% of the total cases of AD 
(Alzheimer’s Association, 2014).
 Sporadic Alzheimer’s disease tends to be late onset, and the risk of developing it increases with 
age and it appears to be caused by the accumulation of a range of risk factors that can vary from 
individual to individual (hence the term sporadic).  Sporadic forms of AD account for the vast majority 
(~95%) of AD cases (Alzheimer’s Association, 2014).  The genetic factors that contribute to sporadic 
AD increase one’s risk of developing AD, probably in the presence of other, non-genetic factors, but 
are not causal by themselves.
As is the case in many genetic disorders, while we can observe the differences in the genetic 
sequence of people who develop familial AD, this does not reveal which properties of the protein 
expressed by that gene are affected, or how this contributes to the pathology.  It does, however, 
provide researchers with some critical clues about where to look.
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GENETIcS IN FAMILIAL ALZHEIMER’S DISEASE
There are several mutations that have been associated with directly inherited familial AD, particularly 
in the genes coding for the amyloid precursor protein (APP) and its processing enzymes.  APP is a 
large protein expressed in neurons that is cleaved into smaller proteins and peptides by several 
processing enzymes called secretases (Selkoe, 1989).  One of the peptides produced from processing 
of APP is amyloid β, the peptide that aggregates into the plaques seen in AD brains (Masters et al., 
1985).  Early investigations into the genetic causes of AD were guided by the discovery that amyloid 
β was the same protein seen in plaques developed in the brains of people with Down syndrome, 
who frequently develop a similar form of dementia (Glenner et al., 1984).  As Down syndrome was 
known to be caused by the presence of an extra copy of chromosome 21, research into potential 
sites of genetic causes for AD were focused around this locus (St George-Hyslop et al., 1987).  This 
assisted in the discovery of the first mutation found in families with AD, a change in the DNA coding 
for the APP gene.  This specific polymorphism came to be referred to as "the Swedish mutation", as it 
was isolated in two Swedish families with genetically caused AD (Murrell et al., 1991; Wisniewski et 
al., 1992).  The Swedish mutation results in a change in the amino acid sequence of APP on either 
side of the site that amyloid β is generated from.  The mutation makes the site more attractive to 
the enzyme that makes this cut, the β-secretase, resulting in increased activity and therefore an 
increased production of amyloid β.  Since this discovery, several other mutations have been identified 
within the APP gene that also lead to an increase in its amyloidogenic processing, thus upregulating 
the amount of amyloid β in the system (Cole et al., 2008).
Other genetic mutations associated with familial AD involve mutations on chromosomes 14 and 1, 
which make changes in the genes encoding components of the γ-secretase, the enzyme that makes 
the second cut into APP to release amyloid β.  This secretase is formed by an assembly of four smaller 
proteins, including presenilins 1 and 2 (Chouraki et al., 2014).  Mutations in the coding sequence for 
presenilin 1 are the most common cause of inherited AD (Piccoli et al., 2016).  In the most common 
form of the mutation, changes cause the γ-secretase to cut slightly downstream of the usual amyloid 
β generating site, resulting in a slightly longer form of amyloid β.  This form of the peptide, referred 
to as Aβ42 because it contains 42 amino acids instead of the usual 38-40, is ‘stickier’ than other 
forms of amyloid β, as the additional amino acids it contains make it more more attractive to other 
amyloid β peptides, causing them to clump together more readily to generate plaques (Haass et al., 
2012).  This sticky form of amyloid β forms into aggregates around synapses, preventing neurons 
from communicating with one another, ending in neuronal death (Scheuner et al., 1996).
Other mutations in the PS1 gene that also cause familial AD result in changes to the secretase 
subunits that alter their charges in minor but significant ways (Piccoli et al., 2016).  These changes 
in the charge across the molecule affect the way it can fold itself around other charged areas, 
disrupting the arrangement of the final construct in such a way that the rate of reactions between 
ϒ-secretases and APP is increased, again contributing to the upregulated expression of amyloid β 
(Nadav et al., 2015).
SPORADIc ALZHEIMER’S DISEASE
Uncovering the genetic factors that contribute to sporadic forms of AD has proven more difficult, 
because the methods rely upon the collection of massive sets of detailed data about the genetic 
sequence of individuals over very large population samples in order to pick up correlations between 
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the presence of a specific mutation and the onset of AD.  This is obviously complicated by the fact that 
some people in the AD-affected population will not have any genetic contribution to their pathology, 
and some people from the unaffected population may possess a risk gene that has not developed 
into AD (Marei et al., 2015).  Further, the use of correlative analysis means that even if a mutation 
is identified as more frequent within the AD-affected population, it may be contributing to another 
factor that increases the risk for AD, such as development of diabetes or vascular problems (Karch 
et al., 2015).  Additionally, many of the mutations associated with an increased risk of AD occur at 
low frequency, meaning that although those who carry the variant consistently have an increased 
risk of AD, the mutated genes may not occur with high frequency within cohorts of AD patients, 
making them particularly hard to detect (Del-Aguila et al., 2015).
Despite these methodological constraints, genome-wide association studies of large cohorts of AD 
patients have identified several mutations that contribute towards an increased risk of developing the 
disease, or towards reducing the age of onset (Chouraki et al., 2014).  These genetic polymorphisms 
affect pathways that include amyloid-β production and clearance, cholesterol processing, immune 
responses, and general protein clearance (Karch et al., 2015; Marei et al., 2015).  The genetic 
variant that confers the highest risk for development of AD without being causal occurs in the gene 
for the apolipoprotein E (ApoE) (Strittmatter et al., 1993).  APOE alleles are found in 3 different 
isoforms, ε2, ε3 and ε4.  Having one allele of the APOEε4 isoform increases the risk of developing 
AD by threefold, and having both alleles as APOEε4 increases risk 12-fold, also reducing the age of 
onset (Corder et al., 1993).  Conversely, it appears that the APOE ε2 isoform may protect against 
the development of AD, as people with at least one allele in this isoform are less likely to develop AD 
than the general population, and if they do it is significantly later in life (Corder et al., 1993).    While 
the mechanism of increased risk or protection is not well understood, ApoE is known to be involved 
with clearance of excess proteins including amyloid β, and can bind with amyloid β to prevent it 
from aggregating into plaques (Kim et al., 2009).
Other mutations that consistently appear to be associated with an increased risk for AD occur in 
the genes coding for SORL1, ADAM10 and TREM2 (Del-Aguila et al., 2015).  SORL1 is the gene 
that codes for sortilin–related receptor L, which is an ApoE receptor, and this mutation results in 
reduced expression of these receptors (Rogaeva et al., 2007).  ADAM10 is a gene that encodes for 
the α-secretase, which cuts APP within the domain that becomes amyloid β, effectively precluding 
its production.  In addition, this nonamyloidogenic processing of APP produces alternative proteins 
that stimulate neuroprotection and neurogenesis, which can help protect against AD symptoms and 
slow down its progress (Furukawa et al., 1996).   AD risk mutations in ADAM10 reduce the activity of 
α-secretase, resulting in reduced neuroprotection while simultaneously facilitating the production of 
amyloid β (Vassar, 2013).  The TREM2 mutation affects the "triggering receptor expressed on myeloid 
cells 2" protein, a receptor expressed on microglial cells (Sims et al., 2017).   Microglia are a type 
of cell in the brain responsible for immunological protection of the neurons, also digesting toxins to 
maintain a balanced, healthy environment for neurons to function properly.  While the mechanism 
of TREM2 mutations in susceptibility to AD is unclear, it is known that microglia are capable of 
removing amyloid plaques, as well as triggering the destruction of dead cells or waste proteins, all 
of which could contribute to worsening AD (Ulrich et al., 2016).   It therefore seems likely that this 
mutation in some way alters the activity of TREM2 receptors, reducing microglial functioning and 
exacerbating AD pathology.
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Genetic contribution to the development of sporadic forms of AD is important, but there are also 
environmental factors that have been consistently associated with an increased risk for sporadic AD. 
For example, sporadic AD is associated with a range of metabolic complications, such as diabetes 
and insulin resistance (Sridhar et al., 2015), hypertension (Yaffe et al., 2014), and high cholesterol 
(Nishimura et al., 2014).  Neurons use a disproportionately high amount of the body’s energy, 
almost exclusively in the form of glucose, so disruptions in glucose availability can have a significant 
detrimental impact on neuron transmission and survival (Schubert, 2005).  The hippocampus, one 
of the first brain regions to be affected by AD, is one of the highest energy-consuming regions of 
the brain, and is therefore particularly vulnerable to disruptions in glucose metabolism (Sun et al., 
2016).  Vascular degeneration is also associated with the onset of sporadic AD, and significantly 
reduces neurogenesis and disturbs glucose exchange and waste removal between brain tissue 
and the blood (Nelson et al., 2016), resulting in increased oxidative stress and the spread of toxic 
amyloid species across the central nervous system (Smith et al., 2009).  Insulin tolerance has 
been directly linked to tau hyperphosphorylation and has been shown to increase amyloidogenic 
processing of APP (Freude et al., 2005).
Longitudinal studies also consistently implicate lifestyle factors such as diet, physical inactivity, 
social isolation/depression, and smoking for increasing the risk of developing sporadic AD (Williams 
et al., 2010).  Imbalances in brain activity such as sleep disruptions and seizures also contribute to 
increased sporadic AD susceptibility (Eshkoor et al., 2013).  As much of the information available 
on risk factors is from longitudinal lifestyle studies, it is difficult to prove contribution to risk rather 
than correlative relationships between these factors and the occurrence of AD because of the high 
interaction between a variety of upstream and downstream factors.  There is, however, evidence 
that the prevalence of AD is reducing in well-developed countries with educational programs in 
place promoting preventative adjustment of lifestyle risk factors such as improvements in lifelong 
physical activity, mental health support and diet (Alzheimer’s Association, 2015). 
Despite the positive steps in reducing the prevalence of AD (the proportion of the population that 
develop the disease), the incidence of AD continues to rise (the total number of people with the 
disease).  This occurs because the risk of developing AD increases with age, and for those at age 
85, there is a 50% incidence rate (Cornutiu, 2015).  Improvements in quality of life and access to 
sophisticated medical care contribute to increases in the number of people living to an age where they 
are likely to develop AD.  So despite improvements in our understanding of potential risk factors and 
the effectiveness of associated education campaigns, the incidence of AD is projected to continue to 
rise (Prince et al., 2016).  In fact, the World Health Organisation estimates that nearly 46.8 million 
people worldwide are currently living with AD, and expects this to increase to 131.5 million by 2050 
(World Health Organisation, 2015).  The global health costs associated with managing AD in 2010 
were US$ 818 billion, and in Australasia, the costs involved in responding to AD account for almost 
1% (0.97%) of the total GDP (Alzheimer’s Disease International, 2016).
Alzheimer’s disease constitutes a serious world health burden, and one that is anticipated to grow. 
Research into AD has largely been guided by the genes that are involved, pointing scientists in the 
direction of proteins and pathways that contribute to the disease. While genetics may not be the 
whole story in conquering all cases of AD, the knowledge imparted from genetic studies has been 
essential in advancing our knowledge of AD pathology and in developing potential therapies, assisting 
researchers to address this critical public health issue for the future.
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